Clinical trial NCT05066646: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)
Official title: Phase 1/2 Clinical Study on Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Multiple Myeloma
Lead sponsor: Nanjing IASO Biotechnology Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2021-10-04
Enrollment: 132
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is a single-armed, open-label, multicenter Phase 1/2 study to evaluate the efficacy and safety of CT103A in subjects with relapsed and refractory MM.

Detailed description: Leukapheresis procedure will be performed to manufacture CT103A chimeric antigen receptor (CAR) modified T cells. Bridging therapy is allowed between PBMC collection and lymphodepletion. Lymphodepletion with fludarabine and cyclophosphamide was performed for three consecutive days. After 1-day rest, subjects will receive a single dose infusion of CT103A at 1.0 x 10\^6 CAR+ T cells/Kg. Subjects will be followed in the study for a minimum of 2 years after CT103A infusion. Long-term follow-up for lentiviral vector safety will be followed for up to 15 years after CT103A infusion.

Eligibility criteria: Inclusion Criteria:

Subjects must satisfy all the following criteria to be enrolled in the study:

1. age 18 to 70 years old, male or female.
2. Subjects with diagnosed relapsed or refractory MM according to IMWG criteria and have had at least 3 prior lines of therapy including chemotherapy based on proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs). Disease progression must be documented during or within 12 months following the most recent anti-myeloma treatment.
3. Evidence of cell membrane BCMA expression, as determined by a validated immunohistochemistry (IHC) or flow cytometry of tumor tissue (e.g., bone marrow biopsies, or plasmacytoma).
4. The subjects should have measurable disease based on at least one of the following parameters:

   * The proportion of primitive immature or monoclonal plasma cells detected by bone marrow cytology, bone marrow biopsy, or flow cytometry is ≥ 5%.
   * Serum M-protein ≥ 0.5 g/dL.
   * Urine M-protein ≥ 200 mg/24 hrs.
   * For those whose Serum or Urine M-protein does not meet the measurable criteria but the light chain type, serum free light chain (sFLC): involved sFLC level ≥ 10 mg/dL (100 mg/L) provided serum FLC ratio is abnormal.
5. ECOG performance score 0-1.
6. Estimated life expectancy ≥ 12 weeks.
7. Patients should have adequate organ function:

   * Hematology: Absolute neutrophil count (ANC) ≥1×10\^9 /L (prior use of growth factor support is permitted, but subjects must not have received supportive treatment within 7 days prior to laboratory examination); absolute lymphocyte count (ALC) ≥0.3×10\^9 /L; platelets ≥50×10\^9 /L (subjects must not have received blood transfusion support within 7 days prior to laboratory examination); hemoglobin ≥60 g/L (subjects must not have received transfusion of red blood cells \[RBC\] within 7 days prior to laboratory examination; the use of recombinant human erythropoietin is permitted).
   * Liver function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5×upper limit of normal (ULN); total serum bilirubin ≤ 1.5×ULN.
   * Renal function: Creatinine clearance rate (CrCl) calculated according to Cockcroft-Gault formula ≥ 40 ml/min.
   * Coagulation function: Fibrinogen ≥ 1.0 g/L; activated partial thromboplastin time (APTT) ≤ 1.5×ULN, prothrombin time (PT) ≤ 1.5×ULN.
   * SpO2 \> 91%.
   * Left ventricular ejection fraction (LVEF) ≥ 50%.
8. The subject and his/her spouse agree to use an effective contraceptive tool or medication (excluding safety period contraception) for one year from the date of the subject's informed consent to the date of CAR T cell infusion.
9. Subject must sign the informed consent form approved by ethics board in person before starting any screening procedure.

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

1. Subjects who are known to have GVHD or need long-term immunosuppressive therapy.
2. Subjects have received an autologous hematopoietic stem cell transplantation (auto-HSCT) within 12 weeks before leukapheresis or have a previous history of two times of allo-HSCT or previous history of an allogeneic hematopoietic stem cell transplantation (allo-HSCT).
3. Insufficient mononuclear cells for CAR T cell production.
4. Subjects have received any anti-cancer treatment as follows: targeted therapies, epigenetic therapy or invasive experimental instruments therapy within 14 days or at least 5 half-lives before leukapheresis (according to the longer time), or monoclonal antibody for treating multiple myeloma within 21 days before leukapheresis, or cytotoxic therapy or proteasome inhibitors within 14 days before leukapheresis, or immunomodulatory agents within 7 days before leukapheresis.
5. Subjects who were receiving a used therapeutic dose of corticosteroid treatment (defined as prednisone or equivalent \> 20mg) within 7 days prior to screening, except for physiological alternatives, inhalation, or topical use.
6. Subjects with serious heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure (NYHA classification ≥III), and severe arrhythmias.
7. Subjects with systemic diseases that the investigator determined to be unstable include, but are not limited to, severe liver and kidney or metabolic diseases requiring medical treatment.
8. Subjects with second malignancies in addition to MM within the past 5 years before the screening, exceptions to this criterion: successfully treated cervical carcinoma in situ and non-metastatic basal or squamous cell skin carcinoma, local prostate cancer after radical surgery, and ductal carcinoma in situ of the breast after radical surgery.
9. Subjects with a history of organ transplantation.
10. Subjects have central nervous system (CNS) involvement (including cranial neuropathies or mass lesions and leptomeningeal disease).
11. Subjects with extramedullary lesions (except for a single extramedullary lesion with a maximum transverse diameter of 3 cm).
12. Subjects with plasma cell leukemia.
13. Subjects have received major surgery within 2 weeks prior to leukapheresis or plan to receive surgery during the study or within 2 weeks after the study treatment (excluding local anesthesia).
14. Subjects participated in another interventional clinical study 3 months before signing the informed consent (ICF);
15. Subjects with any uncontrolled active infection needed to receive systemic therapy within 7 days before leukapheresis collection (excluding \< CTCAE grade 2 urogenital infection and upper respiratory infection).
16. Positive for any of the following tests:

    * Hepatitis B virus (HBV) surface antigen (HBsAg) or hepatitis B core antibody-positive and detectable HBV DNA in peripheral blood
    * Hepatitis C virus (HCV) antibody and hepatitis C virus RNA in peripheral blood
    * Human immunodeficiency virus (HIV) antibody
    * Cytomegalovirus (CMV) DNA
    * Treponema Pallidum antibody
17. Pregnant or lactating women.
18. Subjects with mental illness or consciousness disorder or disease of the central nervous system
19. Subjects who haven't recovery to Grade 1 or baseline of any toxicities due to prior treatments, excluding alopecia.
20. Other conditions that researchers consider inappropriate for inclusion.

Primary outcomes:
measure: Phase 1: Incidence and Severity of Adverse Events
timeFrame: Minimum of 2 years post CT103A infusion
measure: Phase 1: Laboratoty tests
timeFrame: Minimum of 2 years post CT103A infusion
measure: Phase 1: Vital signs
timeFrame: Minimum of 2 years post CT103A infusion
measure: Phase 1: Physical examination
timeFrame: Minimum of 2 years post CT103A infusion
measure: Phase 2: Overall response rate (ORR) evaluated by an Independent Review Committee (IRC)
timeFrame: 3 months post CT103A infusion
Secondary outcomes:
measure: Overall response rate (ORR) evaluated by the investigators
timeFrame: 3 months post CT103A infusion
measure: Overall Survival (OS)
timeFrame: Minimum of 2 years post CT103A infusion
measure: Duration of Response (DOR)
timeFrame: Minimum of 2 years post CT103A infusion
measure: Progression-free Survival (PFS)
timeFrame: Minimum of 2 years post CT103A infusion
measure: Time to Response (TTR)
timeFrame: Minimum of 2 years post CT103A infusion
measure: Laboratoty tests
timeFrame: Minimum of 2 years post CT103A infusion
measure: Vital signs
timeFrame: Minimum of 2 years post CT103A infusion
measure: Physical examination
timeFrame: Minimum of 2 years post CT103A infusion
measure: Minimal Residual Disease (MRD)
timeFrame: Minimum of 2 years post CT103A infusion
measure: Pharmacokinetics - Cmax
timeFrame: Minimum of 2 years post CT103A infusion
measure: Pharmacokinetics - Tmax
timeFrame: Minimum of 2 years post CT103A infusion
measure: Pharmacokinetics - AUC0-28days
timeFrame: Minimum of 2 years post CT103A infusion
measure: Pharmacokinetics - AUC0-90days
timeFrame: Minimum of 2 years post CT103A infusion
measure: soluble BCMA levels
timeFrame: Minimum of 2 years post CT103A infusion
Other outcomes:
measure: Immunogenicity
timeFrame: Minimum of 2 years post CT103A infusion
measure: replication competent lentivirus (RCL)
timeFrame: Minimum of 2 years post CT103A infusion
measure: the levels of CAR-T related inflammatory factors
timeFrame: Minimum of 2 years post CT103A infusion
Locations:
city: Hefei
country: China
facility: Anhui Provincial Cancer Hospital
state: Anhui
city: Zhengzhou
country: China
facility: The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital
state: Henan
city: Wuhan
country: China
facility: Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
state: Hubei
city: Changsha
country: China
facility: The Third Xiangya Hospital of Central South University
state: Hunan
city: Nanjing
country: China
facility: Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University
state: Jiangsu
city: Nanjing
country: China
facility: The Affiliated Hospital of Nanjing University Medical School, Nanjing Drum Tower Hospital
state: Jiangsu
city: Xuzhou
country: China
facility: The Affiliated Hospital of Xuzhou Medical University
state: Jiangsu
city: Hangzhou
country: China
facility: The First Affiliated Hospital, Zhejiang University School of Medicine
state: Zhejiang
city: Beijing
country: China
facility: Beijing Boren Hospital
city: Beijing
country: China
facility: Peking University First Hospital
city: Chongqing
country: China
facility: Xinqiao Hospital, Army Medical University
city: Shanghai
country: China
facility: Fudan University Zhongshan Hospital
city: Shanghai
country: China
facility: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
city: Tianjin
country: China
facility: Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Study officials:
affiliation: Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
name: Lugui Qiu, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Tongji Hospital
name: Chunrui Li, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: